Cequent Pharmaceuticals, a biopharmaceutical company that develops products to deliver RNAi-based treatments for the prevention and treatment of human disease, announced recently that the FDA Center for Biologics Evaluation and Research has approved Cequent’s first investigational new drug (IND) application.
16 December, 2009
An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibiotic drugs.
04 December, 2009
Domainex Ltd. has released the next generation of its LeadBuilder virtual screening technology. LeadBuilder is the proprietary lead generation platform developed by Domainex to provide unusually rapid and cost-effective access to high-quality small-molecule drug leads, particularly against novel or difficult target proteins.
03 December, 2009